Advanced Solid Tumours
iOmx Therapeutics AG focuses on advanced/metastatic solid tumors and previously treated unresectable solid tumours, with clinical activity centred on patients whose disease has progressed after earlier therapy. The sponsored studies include evaluation of IOMX-0675 as a standalone antibody therapy and in combination with pembrolizumab.
- Metastatic solid tumor treatment
- Unresectable solid tumour management
- Anti-tumour immunotherapy
- Combination therapy with pembrolizumab
The research programme is directed toward tumour control in heavily pretreated disease settings across multiple solid tumour types.
Renal Cell Carcinoma
One active area of interest is previously treated clear cell renal cell carcinoma (ccRCC), where the sponsor is assessing therapeutic activity in a refractory genitourinary cancer population.
- Clear cell renal cell carcinoma
- Previously treated disease
- Objective response rate
- Progression-free survival
This focus reflects interest in treatment options for kidney cancer after prior systemic therapy.
Non-Small Cell Lung Cancer
The sponsor also studies previously treated squamous non-small cell lung cancer (sqNSCLC), a major thoracic oncology domain with unmet need in later-line care.
- Squamous non-small cell lung cancer
- Thoracic malignancies
- Tumour response assessment
- Survival outcomes
Clinical evaluation in this setting is aimed at patients with limited options after prior treatment.
Urothelial Carcinoma
iOmx Therapeutics AG includes urothelial carcinoma (UC) among its therapeutic interests, extending its clinical research into bladder and urinary tract cancers that have relapsed or persisted after earlier therapy.
- Urothelial carcinoma
- Bladder cancer
- Previously treated solid tumours
- Anti-cancer efficacy
This area supports investigation of treatment activity across advanced genitourinary malignancies.
Advanced Sarcoma
The sponsor’s research also covers advanced sarcoma (AS), including unresectable previously treated sarcoma, with assessment of antitumour activity in a difficult-to-treat soft tissue cancer population.
- Advanced sarcoma
- Unresectable sarcoma
- Soft tissue cancer
- Independent response review
These studies broaden the sponsor’s oncology portfolio across rare and aggressive solid tumour indications.
